The Quantellect read.As of Nov 19, 2026, 21 active firms cover Alnylam Pharmaceuticals Inc: 17 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $253.00 to $455.00, a moderate spread. The average target of $357.17 sits 139% above the current $149.39. The rating mix has stayed broadly stable, with Buy-side ratings easing from 19 to 17 over recent months. On the fundamentals, the Street sees revenue growth near 51% this year and 30% next, consensus EPS building from about $2.62 next quarter toward $10.83 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 active firms
Buy
Strong Buy15%
Buy1676%
Neutral419%
Sell00%
Strong Sell00%
Based on 21 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$357.17
+139.1% upside
Average target across 18 active firms as of Nov 19, 2026 vs $149.39 current
Highest Target$455.00
Average Target$357.17
Lowest Target$253.00
Detailed analyst forecasts for ALNY
Showing 1–18 of 18 named analysts shown · 21 active firms in the rating projection
As of Nov 19, 2026, 17 of 21 active firms rate ALNY a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ALNY EPS & revenue forecast
EPS · NEXT QUARTER
$2.62
Range $1.80 – $3.24 · 8 analysts · +32% YoY
Next period, 8 analysts expect Alnylam Pharmaceuticals Inc to earn $2.62 a share (range $1.80 – $3.24), versus $1.99 a year earlier. Full-year consensus is $22.68, growing to $10.83 the year after.
REVENUE · NEXT QUARTER
$1.5B
Range $1.3B – $1.8B · 8 analysts · +19% YoY
Revenue is expected to reach $1.5B (range $1.3B – $1.8B), +19.0% year-over-year. Full-year consensus is $5.4B, rising to $6.5B next year.
Top analysts covering Alnylam Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALNY.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$280.00+87.4% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$369.00+147.0% to target
Overall win rate
54%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Buy
$375.00+151.0% to target
Overall win rate
41%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$450.00+201.2% to target
Overall win rate
38%
+ Follow
#5
Joseph Stringer
Needham · Rank #256
Buy
$357.00+139.0% to target
Overall win rate
36%
+ Follow
ALNY stock forecast FAQ
What is ALNY's average 12-month price target?+
The 18 active firms with a live target average $357.17 for Alnylam Pharmaceuticals Inc over the next 12 months, ranging from a $455.00 high to a $253.00 low, as of Nov 19, 2026.
Is ALNY stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 21 active firms as of Nov 19, 2026, 17 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ALNY?+
The Street-high target is $455.00 (HC Wainwright & Co.), and the Street-low is $253.00 (Wells Fargo). The average of all 18 active-firm targets is $357.17.
How many active Wall Street firms cover ALNY?+
21 active firms have a recognized rating on Alnylam Pharmaceuticals Inc as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ALNY?+
Among analysts who currently cover ALNY, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $280.00 target.
What is Alnylam Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $2.62 per share (range $1.80 – $3.24) across 8 analysts. Full-year EPS is projected at $22.68, rising to $10.83 the following year.
How much revenue is Alnylam Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $1.5B (range $1.3B – $1.8B). Full-year revenue is projected at $5.4B, growing to $6.5B next year.
Have analysts been upgrading or downgrading ALNY lately?+
As of Nov 19, 2026, 17 of 21 active firms rate ALNY a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALNY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.